RT Journal Article
SR Electronic
T1 Taller height and risk of coronary heart disease and cancer: a within-sibship Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.16.21260639
DO 10.1101/2021.07.16.21260639
A1 Laurence J Howe
A1 Ben Brumpton
A1 Humaira Rasheed
A1 Bjørn Olav Åsvold
A1 Cristen J Willer
A1 George Davey Smith
A1 Neil M Davies
YR 2021
UL http://medrxiv.org/content/early/2021/07/19/2021.07.16.21260639.abstract
AB Taller people have lower risk of coronary heart disease but higher risk of many cancers. Mendelian randomization studies in unrelated individuals have suggested that these relationships are potentially causal. However, Mendelian randomization estimates from samples of unrelated individuals are sensitive to demography (population stratification, assortative mating) and familial (indirect genetic) effects. Height could influence disease risk via anatomic and physiological effects of height (e.g., number of cells or the bore of arteries) or previous results may have been confounded by early-life environmental factors (e.g., parental socioeconomic position and nutrition).In this study, we performed within-sibship Mendelian randomization analyses using 77,757 siblings, a design robust against demography and indirect genetic effects of parents. Within-sibship Mendelian randomization estimated that one SD taller height lowers odds of coronary heart disease by 14% (95% CI: 3% to 23%) but increases odds of cancer by 18% (95% CI: 3% to 34%). There was some evidence that taller height reduces systolic blood pressure and LDL cholesterol, which may mediate some of the protective effect of taller height on coronary heart disease risk.For the first time, we have demonstrated that purported effects of height on adulthood disease risk are unlikely to be explained by demographic or familial factors, and so likely reflect an individual-level causal effect. Disentangling the mechanisms via which height affects disease risk may improve understanding of the aetiologies of atherosclerosis and carcinogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_00011/1]. NMD is supported by a Norwegian Research Council Grant number 295989.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has ethical approval from the North West Multi-centre Research Ethics Committee (MREC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank individual level participant data are available via enquiry to access{at}ukbiobank.ac.uk. If interested in accessing HUNT data, you can find more information at https://www.ntnu.edu/hunt/data. Example scripts for population and within-sibship models are available on GitHub https://github.com/LaurenceHowe/SiblingGWAS.